Literature DB >> 1902829

Nutritional support and cancer cachexia. Evolving concepts of mechanisms and adjunctive therapies.

E H Ng1, S F Lowry.   

Abstract

Despite the widespread employment of intravenous feeding in patients with cancer cachexia to improve outcome, conflicting data exist regarding the efficacy of such therapy in addressing metabolic alterations secondary to immobility, malnutrition, and disease-specific processes. Persistence of distinct abnormalities of body and tissue integrity and peripheral tissue plasma inter-organ nitrogen flux imply the need for anabolic agents to enhance the therapeutic effects of parenteral nutrition. This article focuses upon potential anabolic agents such as chronic submaximal exercise, hormonal augmentation, pharmacologic intervention, and variations in substrate composition. Finally, the immunologic, metabolic, and endocrine consequences of bypassing the gastrointestinal tract are considered and related to the limited efficacy of current total parenteral nutrition regimens.

Entities:  

Mesh:

Year:  1991        PMID: 1902829

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  6 in total

1.  Muscle wasting and branched-chain amino acid, alpha-ketoglutarate, and ATP depletion in a rat model of liver cirrhosis.

Authors:  Milan Holeček; Melita Vodeničarovová
Journal:  Int J Exp Pathol       Date:  2019-01-13       Impact factor: 1.925

2.  Effects of insulin and insulin-like growth factors on protein and energy metabolism in tumour-bearing rats.

Authors:  F M Tomas; C S Chandler; P Coyle; C S Bourgeois; J L Burgoyne; A M Rofe
Journal:  Biochem J       Date:  1994-08-01       Impact factor: 3.857

Review 3.  Muscle wasting in animal models of severe illness.

Authors:  Milan Holecek
Journal:  Int J Exp Pathol       Date:  2012-05-08       Impact factor: 1.925

4.  Effect of protein-calorie malnutrition on cytochromes P450 and glutathione S-transferase.

Authors:  W Zhang; H Parentau; R L Greenly; C A Metz; S Aggarwal; I W Wainer; T S Tracy
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Apr-Jun       Impact factor: 2.569

5.  Distinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3.

Authors:  Míriam Toledo; Fabio Penna; Sílvia Busquets; Francisco J López-Soriano; Josep M Argilés
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

6.  Are there any benefits of exercise training in cancer cachexia?

Authors:  Josep M Argilés; Sílvia Busquets; Francisco J López-Soriano; Paola Costelli; Fabio Penna
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-05-08       Impact factor: 12.910

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.